What question did this study set out to answer?

To evaluate the rates of overall and site-specific serious infections among patients with active rheumatoid arthritis treated with anti-TNF therapy compared to standard DMARD therapy.

July 25, 2006Arthritis & Rheumatism

Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

View Full Paper

Ask AI

Bookmark

Authors

WDWilliam G DixonManchester Academic Health Science Centre KWK. WatsonBrigham and Women's Hospital MLMark LuntVersus Arthritis

Discussion

Member takes

Implication

Registry cohort study demonstrates increased skin infection rates without overall serious infection elevation in rheumatoid arthritis, highlighting tissue-specific immune defense roles.

Key Points

To evaluate the rates of overall and site-specific serious infections among patients with active rheumatoid arthritis treated with anti-TNF therapy compared to standard DMARD therapy.
Prospective cohort study analyzing data from the British Society for Rheumatology Biologics Register.
Comparison of serious infection risks between anti-TNF recipients and DMARD-treated control subjects, adjusted for baseline infection risk.
Anti-TNF therapy was not associated with an increased risk of overall serious infections compared with DMARD treatment after adjusting for baseline risk.
Patients treated with anti-TNF therapy experienced a significantly elevated rate of serious skin and soft tissue infections relative to DMARD controls.

Cite This Study

Dixon et al. (2006) studied this question.

synapsesocial.com/papers/69d8105b3eff0c9dfaae32b8 https://doi.org/10.1002/art.21978

View Full Paper

Ask AI

Bookmark

Implication

Registry cohort study demonstrates increased skin infection rates without overall serious infection elevation in rheumatoid arthritis, highlighting tissue-specific immune defense roles.

Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

Discussion

Member takes

Implication

Key Points

Cite This Study

Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider